Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price on Monday after it announced today that they secured patents in USA (8912179) and New Zealand (614567) to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action-H3 Inverse agonist and these patents are valid until 2030 and 2031 respectively.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Shares of the company are trading at Rs 255.25, up Rs 6.55, or 2.63% at the Bombay Stock Exchange (BSE) on Monday at 10:31 a.m.
The scrip has touched an intra-day high of Rs 259 and low of Rs 243. The total volume of shares traded at the BSE is 196,658.